What is Carcinotech?
Carcinotech operates at the intersection of biotechnology and advanced manufacturing, developing a sophisticated platform for creating 3D printed living tumors. These models are engineered using patient-derived biopsies, primary cells, immune cells, and cancer stem cells, offering a highly accurate and ethical alternative for drug screening and pre-clinical testing. The company's technology aims to accelerate the development of novel therapeutics and enable more precise personalized medicine strategies, addressing critical needs in the oncology research landscape.
How much funding has Carcinotech raised?
Carcinotech has raised a total of $7.3M across 2 funding rounds:
Other Financing Round
$2M
Other Financing Round
$5.3M
Other Financing Round (2022): $2M with participation from SIS Ventures, TriCapital Advisors, and Eos Advisory
Other Financing Round (2024): $5.3M led by The TRICAPITAL Syndicate, Eos Advisory, SIS Ventures, and Gabriel Investments
Key Investors in Carcinotech
The TRICAPITAL Syndicate
The TRICAPITAL Syndicate is a business angel syndicate based in the Scottish Borders, investing in growth businesses and bringing extensive experience in enterprise building and investment.
Eos Advisory
Eos Advisory is a Scottish investment firm focused on commercializing science and technology, with a portfolio emphasizing quality of life and environmental sustainability.
SIS Ventures
SIS Ventures, part of Social Investment Scotland, invests in impact-led enterprises that address societal challenges, supporting high-impact organizations with mission-aligned finance.
What's next for Carcinotech?
With this substantial infusion of capital, Carcinotech is poised for significant expansion. The recent major strategic investment signals strong confidence from backers in the company's technology and market potential. This financing is expected to fuel further research and development, scale manufacturing capabilities, and potentially broaden the company's market reach. Carcinotech's focus on patient-derived models positions it to play a pivotal role in the future of oncology drug discovery and personalized treatment planning.
See full Carcinotech company page
